Although nicorandil, N-(2-hydroxyethyl) nicotinamide dinitrate, is a nitrate ester, its cardiovascular action differs from that of nitrate compounds in several aspects. In this quantitative angiographic study, the acute coronary dilating effect of intracoronary nicorandil (0.25, 0.50, 1.0mg) was compared with that of isosorbide dinitrate (ISDN; 1.0mg) in 46 patients with or without ischemic heart disease (IHD). Dose-dependent right coronary dilating action was observed by intracoronary administration of nicorandil without any adverse effects. The same degree of right coronary dilation was achieved by the intracoronary application of equivalent doses of ISDN. We conclude that intracoronary administration of nicorandil is beneficial for the supportive treatment of IHD during coronary artery investigation and intervention without the risk of severe systemic hypotension. (Jpn Heart J 36: 699-707, 1955) 
In the protocol using 46 consecutive patients, induction of coronary spasm was attempted by injecting ergometrin maleate into the right coronary artery. Patients were then assigned randomly to four groups to investigate the coronary dilating effect of intracoronary (ic) ISDN and nicorandil administration. Group I patients received is ISDN 1.0mg, followed by is nicorandil 1.0mg. Group II patients received is nicorandil 1.0mg followed by is ISDN 1.0mg. Group III patients received is nicorandil 1.0mg, then ic nicorandil 1.0mg. Group IV patients received ic ISDN 1.0mg, then ic ISDN 1.0mg. The right coronary artery luminal diameter of three normal portions (segments 2, 3, 4PL) were measured before and after drug administration in the same phase of the cardiac cycle. This suggests that a further increase in the coronary diameter by the second drug relative to the first is attributable to the additive effects of two drugs with mutually different pharmacological actions in combined administration (Table, Figures 2, 3 and 4) . For all groups, control angiography revealed no significant intergroup dif-Jpn Heart J November 1995 Figure 4 . The changes in diameter on segment (4PL) of the right coronary artery as in segments (2) and (3). The symbols are the same as in Figure 2 .
ferences in the basal coronary tonus, while angiography following ergometrin maleate loading revealed significant differences in the segment 2 diameter between groups II and IV. However, both angiographies following administration of the first and second drugs revealed no significant differences among any groups or segments. Between the nicorandil-treated group and the ISDN-treated group, no significant difference was noted in the rate of magnification of the coronary arterial diameter following administration of each drug.
Administration of either nicorandil or ISDN as the 1st drug yielded no differences in the luminal diameters. The same was noted with the 2nd drug, suggesting an equivalent coronary dilating effect for the two drugs. Intracoronary injection of nicorandil and ISDN caused neither arrhythmia nor hypotension, at least at the dosage employed in the present study.
DISCION
Nicorandil is a recently developed nicotinamide derivative antianginal drug which has profound dilating and cardioprotective activity following oral administration. The pharmacological properties differ from those of conventional antianginal drugs10),11) Although this drug is a nitrate ester, its cardiovascular action differs from that of nitrate compounds in several respects. Nicorandil markedly increases coronary blood flow in a dose-dependent manner without any significant hemodynamic influences. This agent has little effect on cardiac output, arterial pressure and pulse pressure, and does not decrease myocardial contractility or oxygen consumption. 3) There have been few studies investigating the dose-dependent acute effects of intracoronary nicorandil on intact or stenotic human coronary arteries. A spasmolytic effect of intracoronary nicorandil administration has been reported 18) It is reported that no significant hemodynamic changes were observed after administering nicorandil, except for a slight decrease in venous return.13) Moreover, nicorandil has no influence on the conduction system or on myocardial compliance and contractility.2,3) Nicorandil, as a K channel activator, actually causes hyperpolarization, accelerates membrane repolarizaton and may shorten the effective refractory period (ERP) in cardiac muscle. This tendency is beneficial in the treatment of arrhythmia based on partial depolarization or a long and dispersed refractory period. 18, 19) This agent is also reported to suppress abnormal automaticiy.1) Proarrhythmic effects of nicorandil which shorten the absolute value of ERP have actually been reported.20) However, this agent is reported to cause a relative prolongation of ERP compared with the action potential duration (APD), 19 ) and the important index governing the reentrant arrhythmogenicity is the ratio of ERP/APD. In any case, neither arrhythmogenic accident nor conduction disturbance was observed in this study under the obvious coronary dilation induced by nicorandil at this dose range.
As a limitation, we admit that serial intracoronary drug delivery is not the best way to compare the vasodilatory ability of each drug or investigate the doseresponsiveness. However, this problem is irrelevant because there was no change in the effect when we changed the sequence of drug application. At present, nitrate compounds are used to improve coronary blood flow and to relieve coronary spasm, but intracoronary administration of nicorandil (1.0mg as the minimum effective dose) is also concluded to be an effective and safe strategy for the same purposes. In conclusion, nicorandil has a coronary vasodilating effect, which is almost equivalent to that of ISDN. This agent may be useful for the treatment of IHD, and as a supportive agent during percutaneous transluminal coronary recanalization and angioplasty.
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